[Study Evaluating the Efficacy and Safety of a Digital Therapeutic as an Adjunct to TAU in Postpartum Depression]

NCT ID: NCT05551195

Last Updated: 2025-02-24

Basic Information

• Recruitment Status: TERMINATED
• Clinical Phase: NA
• Total Enrollment: 7 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2022-11-16
• Study Completion Date: 2023-05-10

Brief Summary

This study evaluates the efficacy of two digital therapeutics, WB001 and ED001, on depressive symptoms among women diagnosed with postpartum depression.

Detailed Description

This randomized, double-blind, controlled trial evaluates the efficacy and safety of 8 weeks of treatment of two digital therapeutics in a population of women with mild to moderate postpartum depression. Patients will be referred by an obstetrician, pediatrician, or other healthcare professional, or by other digital and site based recruitment methods and, if interested, will complete the pre-screening process. Those confirmed as eligible will be scheduled to attend a screening/baseline onsite visit. Eligible participants will be randomized to one of the two groups and will receive instructions on downloading and using the smartphone application to which they were randomized. Participants will use the app as instructed and will attend telehealth visits to complete assessments for the primary and safety endpoints at Weeks 4 and 8 (EOT).

Conditions

Postpartum Depression

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: TRIPLE

Study Groups

WB001 with adjunctive Treatment as Usual

Participants randomized to the WB001 + TAU group will be asked to download and use the study application.

Group Type: OTHER

WB001

Intervention Type: DEVICE

WB001 is a digital therapeutic for postpartum depression.

Educational Control (ED001) with adjunctive Treatment as Usual

Participants randomized to the ED001 + TAU group will be asked to download and use the study application.

Group Type: OTHER

ED001

Intervention Type: DEVICE

ED001 is a digital therapeutic for postpartum depression.

Interventions

WB001

WB001 is a digital therapeutic for postpartum depression.

Intervention Type: DEVICE

ED001

ED001 is a digital therapeutic for postpartum depression.

Intervention Type: DEVICE

Eligibility Criteria

Inclusion Criteria

1. Must have primary residence in the United States

2. Must be ≤ 92 days postpartum

3. Must be women aged 22-45 years who had onset of a major depressive episode any time during pregnancy or within 4 weeks following delivery

4. Must own or have regular access to a smartphone (Android or iOS smartphone with a recent, supported operating system), and has reliable Wi-Fi access or sufficient data plan to engage with assigned treatment condition for the duration of the study

5. Participants must have current mild-moderate depression as measured by the HAMD-6 score >7 and <13 at screening

6. Participant must have a form of TAU, defined as clinician supervised outpatient care management and includes follow-up visits, medication, psychotherapy, or some combination thereof

7. TAU must be regularly scheduled or stable for at least 4 weeks prior to baseline (BL) visit

Exclusion Criteria

1. Gestation less than 28 weeks

2. HAMD-6 score ≤7 or ≥13 (severe depression) at screening

3. Currently pregnant or plans to become pregnant within the next 8 weeks

4. History of drug and/or alcohol use disorder within the past 12 months

5. Lifetime history of suicide attempt or ideation with a plan and intent to harm oneself during the current episode of PPD

6. Current or lifetime psychosis

7. Current or lifetime history of schizophrenia, schizoaffective disorder, bipolar disorder, and/or homicidal or infanticidal ideation

8. History of antidepressant treatment with ketamine/esketamine, electroconvulsive therapy, vagal nerve stimulation, or a deep brain stimulation device

9. History of treatment-resistant depression (TRD)

10. Fetal demise within the past 18 months

• Minimum Eligible Age: 22 Years
• Maximum Eligible Age: 45 Years
• Eligible Sex: FEMALE
• Accepts Healthy Volunteers: No

Sponsors

Woebot Health

INDUSTRY

Sponsor Role: lead

Iqvia Pty Ltd

INDUSTRY

Sponsor Role: collaborator

Responsible Party

Responsibility Role: SPONSOR

Locations

Woebot Investigational Site

Lafayette, California, United States

Woebot Investigational Site

Santa Ana, California, United States

Woebot Investigational Site

DeLand, Florida, United States

Woebot Investigational Site

Miami Lakes, Florida, United States

Woebot Investigational Site

Seminole, Florida, United States

Woebot Investigational Site

Decatur, Georgia, United States

Woebot Investigational Site

Glen Oaks, New York, United States

Woebot Investigational Site

Cleveland, Ohio, United States

Countries

United States

Provided Documents

Document Type: Study Protocol and Statistical Analysis Plan

View Document

Other Identifiers

WB001-001

Identifier Type: -

Identifier Source: org_study_id